Abstract
Masitinib mesylate is a tyrosine-kinase inhibitor approved for the treatment of nonresectable or recurrent, Grade 2 or 3 mast cell tumors in dogs. This report describes nephrotic syndrome and acute kidney injury attributed to masitinib and illustrates the need for regular monitoring of serum creatinine concentration, urinalysis, and urine protein: creatinine ratio during its use.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 752-756 |
| Number of pages | 5 |
| Journal | Canadian Veterinary Journal |
| Volume | 57 |
| Issue number | 7 |
| State | Published - Jul 2016 |